Sanofi
SNYHealthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
Follow SNY
Alert me
Where the cash went Q3 FY2026, quarter to Sep 30, 2026
Free cash flow was $4.4B, and none of it went on dividends or buybacks. Cash fell by $426.6M. Lines the picture does not name came to −$4.8B. What is a cash flow statement?
- Free cash flow
- $4.4B 100.0% of operating cash flow
- Returned to shareholders
- $0.00 0.00% of free cash flow
- Debt, net
- $0.00 borrowed
- Change in cash
- −$426.6M over the period
| Operating cash flow | 4.4 |
|---|---|
| Free cash flow | 4.4 |
| Other | −4.8 |
| Change in cash | −0.4 |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Operating Cash Flow |
4,401.20 | 5,398.42 | — | 12,162.55 |
+8 more quarters Free account |
Investing cash flow |
(591.77) | (3,073.02) | — | (2,768.54) | |
Financing cash flow |
(4,234.68) | (3,874.12) | — | (9,285.40) | |
Exchange Rate Adjustment |
(1.37) | 22.09 | — | (53.18) | |
Discontinued Operations and Adjustments |
— | — | — | 188.94 | |
Change in Cash |
(426.62) | (1,526.62) | — | 244.38 | |
Beginning Cash |
(89.66) | 8,909.77 | — | 8,418.75 | |
Ending Cash |
(516.28) | 7,383.15 | — | 8,663.13 | |
Dividends Paid (Common) |
5,753.04 | (5,753.04) | 0.00 | (5,442.03) | |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 |